---
title: 'NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy
  for Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis'
date: '2024-01-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38190183/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240109170715&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis,
  NALIRIFOX and FOLFIRINOX were associated with similar PFS and OS as first-line treatment
  of advanced PDAC, although NALIRIFOX was associated with a different toxicity profile.
  Careful patient selection, financial toxic effects consideration, and direct comparison
  between FOLFIRINOX and NALIRIFOX are ...'
disable_comments: true
---
CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, NALIRIFOX and FOLFIRINOX were associated with similar PFS and OS as first-line treatment of advanced PDAC, although NALIRIFOX was associated with a different toxicity profile. Careful patient selection, financial toxic effects consideration, and direct comparison between FOLFIRINOX and NALIRIFOX are ...